HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
MCOLN1
mucolipin TRP cation channel 1
Chromosome 19 Β· 19p13.2
NCBI Gene: 57192Ensembl: ENSG00000090674.17HGNC: HGNC:13356UniProt: Q9GZU1
133PubMed Papers
22Diseases
0Drugs
131Pathogenic Variants
FUNCTIONAL ROLE
Ion ChannelTransporter
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
iron ion transmembrane transporter activityprotein bindingplasma membranephagosome maturationmucolipidosis type IVLisch epithelial corneal dystrophygenetic disorderneurodegenerative disease
✦AI Summary

MCOLN1 (mucolipin TRP cation channel 1) is a lysosomal calcium and cation channel that plays a central role in autophagy regulation and lysosomal homeostasis. As a nonselective cationic channel localized to late endosomes and lysosomes 1, MCOLN1 mediates the release of divalent cations including Ca2+, Zn2+, and Fe2+ from lysosomes to the cytosol 21. MCOLN1 regulates multiple cellular processes by controlling lysosomal ionic balance, including endocytosis, exocytosis, lysosomal biogenesis, and autophagy completion 1. Mechanistically, MCOLN1 activity is regulated by the AMPK-PIKFYVE-PtdIns(3,5)P2 pathway 3, and zinc influx through MCOLN1 blocks autophagosome-lysosome fusion by disrupting STX17-VAMP8 SNARE interactions 2. Additionally, MCOLN1-mediated lysosomal exocytosis triggered by AKT phosphorylation promotes ferroptosis defense 4, and MCOLN1 participates in mitochondrial quality control through ROS-activated calcium release 5. Clinically, MCOLN1 mutations cause Lisch epithelial corneal dystrophy (autosomal dominant) 6 and mucolipidosis IV 7. MCOLN1 represents a therapeutic target: agonists (ML-SA5, MK6-83) suppress oncogenic autophagy in multiple cancer types 2, while selective inhibition may enhance ferroptosis sensitivity in AKT-hyperactivated cancers 4.

Sources cited
1
As a nonselective cationic channel localized to late endosomes and lysosomes , MCOLN1 mediates the release of divalent cations including Ca2+, Zn2+, and Fe2+ from lysosomes to the cytosol , .
PMID: 38522082
2
Mechanistically, MCOLN1 activity is regulated by the AMPK-PIKFYVE-PtdIns(3,5)P2 pathway , and zinc influx through MCOLN1 blocks autophagosome-lysosome fusion by disrupting STX17-VAMP8 SNARE interactions .
PMID: 30917721
3
As a nonselective cationic channel localized to late endosomes and lysosomes , MCOLN1 mediates the release of divalent cations including Ca2+, Zn2+, and Fe2+ from lysosomes to the cytosol , .
PMID: 33890549
4
Additionally, MCOLN1-mediated lysosomal exocytosis triggered by AKT phosphorylation promotes ferroptosis defense , and MCOLN1 participates in mitochondrial quality control through ROS-activated calcium release .
PMID: 38924427
5
Additionally, MCOLN1-mediated lysosomal exocytosis triggered by AKT phosphorylation promotes ferroptosis defense , and MCOLN1 participates in mitochondrial quality control through ROS-activated calcium release .
PMID: 39169179
6
Clinically, MCOLN1 mutations cause Lisch epithelial corneal dystrophy (autosomal dominant) and mucolipidosis IV .
PMID: 38359414
7
Clinically, MCOLN1 mutations cause Lisch epithelial corneal dystrophy (autosomal dominant) and mucolipidosis IV .
PMID: 30335591
Disease Associationsβ“˜22
mucolipidosis type IVOpen Targets
0.85Strong
Lisch epithelial corneal dystrophyOpen Targets
0.72Strong
genetic disorderOpen Targets
0.52Moderate
neurodegenerative diseaseOpen Targets
0.39Weak
mucolipidosisOpen Targets
0.34Weak
Intellectual disabilityOpen Targets
0.32Weak
Corneal opacityOpen Targets
0.32Weak
Atrophy/Degeneration affecting the brainstemOpen Targets
0.32Weak
Delayed myelinationOpen Targets
0.32Weak
Delayed speech and language developmentOpen Targets
0.32Weak
Growth delayOpen Targets
0.32Weak
periventricular leukomalaciaOpen Targets
0.32Weak
Abnormality of the nervous systemOpen Targets
0.27Weak
hereditary spastic paraplegia 39Open Targets
0.12Weak
hereditary spastic paraplegia 5AOpen Targets
0.12Weak
Retinal dystrophyOpen Targets
0.11Weak
Alzheimer diseaseOpen Targets
0.10Weak
neoplasmOpen Targets
0.10Suggestive
glioblastoma multiformeOpen Targets
0.09Suggestive
melanomaOpen Targets
0.08Suggestive
Corneal dystrophy, Lisch epithelialUniProt
Mucolipidosis 4UniProt
Pathogenic Variants131
NM_020533.3(MCOLN1):c.406-2A>GPathogenic
Mucolipidosis type IV|not provided|Mucolipidosis|Lisch epithelial corneal dystrophy;Mucolipidosis type IV|Clear cell carcinoma of kidney|Thyroid cancer, nonmedullary, 1|Ovarian serous cystadenocarcinoma
β˜…β˜…β˜†β˜†2026
NM_020533.3(MCOLN1):c.973_984+10delLikely pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2026
NM_020533.3(MCOLN1):c.964C>T (p.Arg322Ter)Pathogenic
Mucolipidosis type IV|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 322
NM_020533.3(MCOLN1):c.1047dup (p.Phe350fs)Pathogenic
Mucolipidosis type IV|Inborn genetic diseases|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 350
NM_020533.3(MCOLN1):c.95dup (p.Pro33fs)Pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 33
NM_020533.3(MCOLN1):c.1207C>T (p.Arg403Cys)Pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 403
NM_020533.3(MCOLN1):c.694A>C (p.Thr232Pro)Pathogenic
Mucolipidosis type IV|not provided|Lisch epithelial corneal dystrophy;Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 232
NM_020533.3(MCOLN1):c.327C>G (p.Tyr109Ter)Pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 109
NM_020533.3(MCOLN1):c.832C>T (p.Gln278Ter)Pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 278
NM_020533.3(MCOLN1):c.680+1G>APathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025
NM_020533.3(MCOLN1):c.1336G>T (p.Val446Leu)Likely pathogenic
Mucolipidosis type IV|Inborn genetic diseases|Lisch epithelial corneal dystrophy;Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 446
NM_020533.3(MCOLN1):c.871C>T (p.Gln291Ter)Pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 291
NM_020533.3(MCOLN1):c.304C>T (p.Arg102Ter)Pathogenic
Mucolipidosis type IV|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 102
NM_020533.3(MCOLN1):c.920del (p.Leu307fs)Pathogenic
Mucolipidosis type IV|Lisch epithelial corneal dystrophy;Mucolipidosis type IV|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 307
NM_020533.3(MCOLN1):c.1453_1463dup (p.Ser488fs)Pathogenic
Mucolipidosis type IV|Lisch epithelial corneal dystrophy;Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 488
NM_020533.3(MCOLN1):c.1149C>G (p.Tyr383Ter)Likely pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 383
NM_020533.3(MCOLN1):c.572-2A>CLikely pathogenic
Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025
NM_020533.3(MCOLN1):c.615dup (p.Ser206fs)Pathogenic
not provided|Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 206
NM_020533.3(MCOLN1):c.1084G>T (p.Asp362Tyr)Pathogenic
Mucolipidosis type IV|not provided|MCOLN1-related disorder|Lisch epithelial corneal dystrophy;Mucolipidosis type IV
β˜…β˜…β˜†β˜†2025β†’ Residue 362
NM_020533.3(MCOLN1):c.984+1G>APathogenic
Mucolipidosis type IV|Mucolipidosis type IV;Lisch epithelial corneal dystrophy|not provided
β˜…β˜…β˜†β˜†2025
View on ClinVar β†—
Related Genes
TFEBProtein interaction86%FRMD6Protein interaction83%PNPLA6Protein interaction78%TRPC5Protein interaction78%PDCD6Protein interaction78%NEU3Protein interaction77%
Tissue Expression6 tissues
Lung
100%
Liver
56%
Ovary
37%
Brain
35%
Heart
31%
Bone Marrow
27%
Gene Interaction Network
Click a node to explore
MCOLN1TFEBFRMD6PNPLA6TRPC5PDCD6NEU3
PROTEIN STRUCTURE
Preparing viewer…
PDB9HJ8 Β· 2.10 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.90LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.71 [0.56–0.90]
RankingsWhere MCOLN1 stands among ~20K protein-coding genes
  • #3,489of 20,598
    Most Researched133 Β· top quartile
  • #592of 5,498
    Most Pathogenic Variants131 Β· top quartile
  • #8,050of 17,882
    Most Constrained (LOEUF)0.90
Genes detectedMCOLN1
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
PMID: 30335591
Autophagy Β· 2019
1.00
2
MCOLN1/TRPML1 finely controls oncogenic autophagy in cancer by mediating zinc influx.
PMID: 33890549
Autophagy Β· 2021
0.90
3
TRPML1 triggers ferroptosis defense and is a potential therapeutic target in AKT-hyperactivated cancer.
PMID: 38924427
Sci Transl Med Β· 2024
0.80
4
IC3D Classification of Corneal Dystrophies-Edition 3.
PMID: 38359414
Cornea Β· 2024
0.70
5
Mitochondrial respiratory chain deficiency inhibits lysosomal hydrolysis.
PMID: 30917721
Autophagy Β· 2019
0.60